Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Nye

Vascular Surgery Peoria, AZ Doctor of Osteopathy

NPI 1558623793 CMS profile 977285

9192 W Union Hills Dr, Peoria, AZ 85382

Open in the dashboard

General payments

$7,425

73 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Nye of Peoria, AZ is reported in the CMS Open Payments database as having received $7,425 across 73 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $214 11
2024 General $106 5
2023 General $206 10
2022 General $339 17
2021 General $129 7
2020 General $141 9
2019 General $6,290 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Nye
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to David Nye were reported at $214. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year David Nye Vascular Surgery median Middle half National median
2019 $6,290 $796 $226–$2,363 $163
2020 $141 $348 $118–$1,110 $114
2021 $129 $471 $158–$1,421 $132
2022 $339 $725 $222–$2,183 $149
2023 $206 $836 $257–$2,440 $160
2024 $106 $909 $252–$2,619 $164
2025 $214 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $5,175 2 payments
  2. Silk Road Medical, Inc. $998 9 payments
  3. Cordis US Corp. $296 16 payments
  4. W. L. Gore & Associates, Inc. $130 3 payments
  5. Philips Electronics North America Corporation $122 5 payments
  6. Janssen Pharmaceuticals, Inc $97 5 payments
  7. Tactile Systems Technology Inc $85 4 payments
  8. Boston Scientific Corporation $67 4 payments
  9. Pfizer Inc. $61 3 payments
  10. E.R. Squibb & Sons, L.L.C. $54 3 payments
  11. Other $338 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $5,000 1 payment
  2. Food and Beverage $1,646 68 payments
  3. Travel and Lodging $780 4 payments
Products named General payments · program years 2019–2025
  1. Endurant $5,175 2 payments
  2. ENROUTE Transcarotid Neuroprotection System $973 8 payments
  3. ENROUTE Transcarotid Stent System $973 8 payments
  4. ENHANCE Transcarotid Peripheral Access Kit $973 8 payments
  5. ENROUTE 0.014 Guidewire $973 8 payments
  6. VIABAHN Endoprosthesis with Heparin Bioactive Surface $98 1 payment
  7. XARELTO $97 5 payments
  8. Flexitouch Plus $70 3 payments
  9. ELIQUIS $61 3 payments
  10. MYNXGRIP $56 3 payments
  11. Other $1,095 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

107

Median for General Surgery: 59

Drug cost

$30,687

Median for General Surgery: $393

Branded share of claims

100%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 19 $17,892
Eliquis Apixaban Brand 12 $12,019
Clopidogrel Clopidogrel Bisulfate Brand 76 $777

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$26,910,917

Of which drugs: $22,755,816

Medicare patients

943

Average age 76

Services billed

24,728

542 women, 401 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 41%
Chronic kidney disease 31%
Ischemic heart disease 27%
Depression 26%
Heart failure 19%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Neostim tl, per square centimeter Q4265 Office 22 5,258 $8,560,569
Amnio quad-core, per square centimeter Q4294 Office 24 3,708 $6,592,550
Restorigin, per square centimeter Q4191 Office 21 2,739 $3,248,494

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

73 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record